Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575500 | 1.00 | RAB9A (0.73) | RAB9ANPC1TP53THRBGRIN2B | |
| SCHEMBL1574803 | 0.99 | RAB9A (0.71) | RAB9ANPC1TP53THRBGRIN2B | |
| SCHEMBL1576140 | 0.90 | TP53 (0.78) | RAB9ANPC1TP53THRBMAPT | |
| SCHEMBL1575182 | 0.90 | TP53 (0.78) | RAB9ANPC1TP53THRBMAPT | |
| SCHEMBL1574412 | 0.89 | RAB9A (0.60) | RAB9ANPC1TP53THRBGRIN2B | |
| SCHEMBL4492029 | 0.88 | TP53 (0.80) | RAB9ANPC1TP53THRBGRIN2B | |
| SCHEMBL1574965 | 0.88 | RAB9A (0.74) | RAB9ANPC1TP53THRBGRIN2B | |
| SCHEMBL11061389 | 0.85 | RAB9A (1.00) | RAB9ANPC1THRBGRIN2BMAPT | |
| SCHEMBL1574784 | 0.84 | GAA (0.57) | RAB9ANPC1TP53MAPT | |
| SCHEMBL1574660 | 0.84 | GAA (0.57) | RAB9ANPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | RAB9A 898/4885NPC1 413/4885TP53 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.